Results 61 to 70 of about 37,349 (258)

Patient-operated imaging for clinical assessment: regulatory and reimbursement challenges in European health systems

Frontiers in Digital Health
BackgroundPatient-operated medical technologies are increasingly integrated into European care. Under EU regulation, CE marking confirms safety and performance for each specific intended use, while reimbursement requires separate demonstration of ...
Chifra Fenton, Chifra Fenton, Charles Tibi, Jacob Glazer, Jacob Glazer, Nadia Prisant, Nadia Prisant   +6 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Telemedicine Public Reimbursement Models for National and Subnational Jurisdictions: Scoping Review

Journal of Medical Internet Research
BackgroundTelemedicine has transformed health care delivery, offering improved access, efficiency, and potentially cost-effectiveness. However, wide-scale implementation is challenged due to multiple factors.
Evan Huang-Ku, Panchanok Muenkaew, Kinanti Khansa Chavarina, Yin May Tun, Zin Nwe Win, Wanrudee Isaranuwatchai, Saudamini Vishwanath Dabak, Natasha Howard   +7 more
doaj   +1 more source

„Pay-back” mechanism in the Polish reimbursement system - analysis and appraisal

Journal of Health Policy & Outcomes Research, 2014
The text of this review has been based on a diploma thesis, prepared by Mr Borys Podgorny under the supervision of Dr Iwona Skrzekowska-Baran, as part of the XXII Edition of the Advanced Management Training in Pharmacoeconomics, HTA, Pharma Marketing and Law of the Warsaw University Of Technology Business School.
openaire   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Retrospective or Prospective Reimbursement Systems: Evaluating the Efficiency of the Global Payment System in Public Hospitals in Bushehr Province [PDF]

Iranian South Medical Journal
Background: Reimbursement systems play an important role in controlling costs and improving hospital efficiency. This study aimed to compare the billing costs of procedures subject to global tariffs with the notified tariffs for the same procedures to ...
Habib Omranikhoo, Mohbubeh Shahbazifard, Mahdieh Ardaneh, Mahdi Rezaee   +3 more
doaj  

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Acceptability to general practitioners of national health insurance and capitation as a reimbursement mechanism.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996
To determine general practitioners' attitudes to national health insurance (NHI) and to capitation as a mechanism of reimbursement. To explore determinants of these attitudes.Cross-sectional survey by means of telephone interviews; four focus group discussions.Cape Peninsula.174 GPs randomly sampled from a total population of 874.Acceptance of NHI ...
Blecher, M.S., Bachmann, M.O., McIntyre, D.   +2 more
openaire   +2 more sources